Advanced search
Publication Cover
Cancer Biology & Therapy Volume 20, 2019 - Issue 5
Submit an article Journal homepage
1,768
Views
5
CrossRef citations to date
0
Altmetric
Research Paper

Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma

Xiuyun LinInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China;Fujian Medical University Union Hospital, Fuzhou, ChinaCorrespondence[email protected]
View further author information
,
Tao ZengImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Jiani XiongInstitute of Immunotherapy, Fujian Medical University, Fuzhou, ChinaView further author information
,
Qiong ZhangInstitute of Immunotherapy, Fujian Medical University, Fuzhou, ChinaView further author information
,
Pan JiangInstitute of Immunotherapy, Fujian Medical University, Fuzhou, ChinaView further author information
,
Xiufeng LiImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Shuchun LinInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China;Fujian Medical University Union Hospital, Fuzhou, ChinaView further author information
,
Qianqian XuImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Huanjiao WengImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Haichun LaiInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China;Fujian Medical University Union Hospital, Fuzhou, ChinaView further author information
,
Huichun GongImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Jinxiang LinImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Niangmei ChengInstitute of Immunotherapy, Fujian Medical University, Fuzhou, ChinaView further author information
,
Xinling TianImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Yunlu XuInstitute of Immunotherapy, Fujian Medical University, Fuzhou, ChinaView further author information
,
Shubin FangInstitute of Immunotherapy, Fujian Medical University, Fuzhou, ChinaView further author information
,
Rong JinImmunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, ChinaView further author information
,
Zhiwei ChenFuzhou Center for Disease Control and Prevention, Fuzhou, ChinaView further author information
,
Jianbo YangDepartment of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minesota, USAView further author information
,
Luke MortonDepartment of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minesota, USAView further author information
,
Bevan YuehDepartment of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minesota, USAView further author information
&
Jizhen LinInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China;Fujian Medical University Union Hospital, Fuzhou, China;Department of Otolaryngology, Medical School, University of Minnesota, Minneapolis, Minesota, USAView further author information
 show all
Pages 666-679 | Received 08 Aug 2018, Accepted 15 Nov 2018, Published online: 20 Dec 2018

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.